A20 cells

{{Short description|Cell line}}

A20 cells, also called ATCC TIB-208, is a cell line originally derived from B-cell lymphoma in an old BALB/c mouse.{{cite journal |last1=Kim |first1=KJ |last2=Kanellopoulos-Langevin |first2=C |last3=Merwin |first3=RM |last4=Sachs |first4=DH |last5=Asofsky |first5=R |title=Establishment and characterization of BALB/c lymphoma lines with B cell properties. |journal=Journal of Immunology |year=1979 |volume=122 |issue=2 |pages=549–554 |doi=10.4049/jimmunol.122.2.549 |pmid=310843 |doi-access=free }} AT20 cells are BALB/c lymphoma cells derived from spontaneous reticulum cell neoplasm.{{Cite journal |last1=Priem |first1=Dario |last2=van Loo |first2=Geert |last3=Bertrand |first3=Mathieu J. M. |date=2020-05-01 |title=A20 and Cell Death-driven Inflammation |url=https://www.sciencedirect.com/science/article/pii/S1471490620300399 |journal=Trends in Immunology |language=en |volume=41 |issue=5 |pages=421–435 |doi=10.1016/j.it.2020.03.001 |pmid=32241683 |s2cid=214771288 |issn=1471-4906|url-access=subscription }} ATCC TIB-208 cells originated from B-cell lymphoma in the reticulum cell sarcoma of an elderly BALB/c mouse.{{Cite web |title=A20: Modeling B cell lymphoma in mice |url=https://drugdevelopment.labcorp.com/industry-solutions/oncology/preclinical/tumor-spotlights/a20-modeling-b-cell-lymphoma-mice.html |access-date=2022-12-05 |website=drugdevelopment.labcorp.com}} A20 cells are used in medical research such as drug screening or vaccine target selection.{{cite journal |last1=Meziane el |first1=K |last2=Bhattacharyya |first2=T |last3=Armstrong |first3=AC |last4=Qian |first4=C |last5=Hawkins |first5=RE |last6=Stern |first6=PL |last7=Dermime |first7=S |title=Use of adenoviruses encoding CD40L or IL-2 against B cell lymphoma. |journal=International Journal of Cancer |date=2004-10-10 |volume=111 |issue=6 |pages=910–920 |doi=10.1002/ijc.20332 |pmid=15300803 |doi-access=free }}{{cite journal |last1=Siegel |first1=S |last2=Wagner |first2=A |last3=Kabelitz |first3=D |last4=Marget |first4=M |last5=Coggin J |first5=Jr |last6=Barsoum |first6=A |last7=Rohrer |first7=J |last8=Schmitz |first8=N |last9=Zeis |first9=M |s2cid=9814435 |title=Induction of cytotoxic T-cell responses against the oncofetal antigen-immature laminin receptor for the treatment of hematologic malignancies. |journal=Blood |date=2003-12-15 |volume=102 |issue=13 |pages=4416–23 |doi=10.1182/blood-2003-01-0198 |pmid=12869512 |doi-access=free }}{{cite journal |last1=Siegel |first1=S |last2=Wagner |first2=A |last3=Schmitz |first3=N |last4=Zeis |first4=M |title=Induction of antitumour immunity using survivin peptide-pulsed dendritic cells in a murine lymphoma model. |journal=British Journal of Haematology |year=2003 |volume=122 |issue=6 |pages=911–4 |doi=10.1046/j.1365-2141.2003.04535.x |pmid=12956760 |doi-access=free }} A20 cells are also highly responsive to immunomodulatory antibodies, and are therefore used frequently in immunotherapy drug studies.